Quinn Opportunity Partners’s Structure Therapeutics GPCR Stock Holding History

Quinn Opportunity Partners’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$537K	Hold	10,000	–	–	0.02%	270
2026 Q1	$482K	Sell	10,000 -15,000	-60%	-$1.03M	0.03%	273
2025 Q4	$1.74M	Sell	25,000 -17,000	-40%	-$694K	0.07%	187
2025 Q3	$1.18M	Hold	42,000	–	–	0.08%	174
2025 Q2	$871K	Buy	42,000 +20,000	+91%	+$440K	0.07%	198
2025 Q1	$381K	Buy	22,000 +10,000	+83%	+$245K	0.03%	294
2024 Q4	$325K	Hold	12,000	–	–	0.02%	298
2024 Q3	$527K	Hold	12,000	–	–	0.05%	190
2024 Q2	$471K	Buy	+12,000	New	+$493K	0.05%	181

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Quinn Opportunity Partners's GPCR Position: Q2 2026 in Review

Quinn Opportunity Partners held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 10,000 shares worth $537K. The position accounts for 0.02% of the portfolio, ranked #270.

Quinn Opportunity Partners first reported a position in GPCR in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.74M in Q4 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Quinn Opportunity Partners held 10,000 shares of Structure Therapeutics worth $537K as of Q2 2026.
Quinn Opportunity Partners left its Structure Therapeutics share count unchanged in Q2 2026.
Structure Therapeutics made up 0.02% of Quinn Opportunity Partners's portfolio in Q2 2026, its #270 holding.
Quinn Opportunity Partners first reported a position in Structure Therapeutics in Q2 2024 and has held it in 9 quarters since.
Quinn Opportunity Partners's Structure Therapeutics position peaked at $1.74M in Q4 2025.
191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Quinn Opportunity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.